DNA Stock Overview
Engages in the leisure and entertainment business in the Asia Pacific region.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Donaco International Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.036 |
| 52 Week High | AU$0.052 |
| 52 Week Low | AU$0.032 |
| Beta | 1.45 |
| 1 Month Change | 5.88% |
| 3 Month Change | n/a |
| 1 Year Change | -16.28% |
| 3 Year Change | -45.45% |
| 5 Year Change | -56.63% |
| Change since IPO | -97.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| DNA | AU Hospitality | AU Market | |
|---|---|---|---|
| 7D | 0% | 8.9% | 1.3% |
| 1Y | -16.3% | 0.8% | 8.8% |
Return vs Industry: DNA underperformed the Australian Hospitality industry which returned 0.8% over the past year.
Return vs Market: DNA underperformed the Australian Market which returned 8.8% over the past year.
Price Volatility
| DNA volatility | |
|---|---|
| DNA Average Weekly Movement | 10.2% |
| Hospitality Industry Average Movement | 5.2% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: DNA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DNA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Techatut Sukjaroenkraisri Huy | www.donacointernational.com |
Donaco International Limited engages in the leisure and entertainment business in the Asia Pacific region. It operates Star Vegas Resort & Club, a casino and hotel complex in Poipet, Cambodia; and Aristo International Hotel, a boutique casino in northern Vietnam. The company was incorporated in 1990 and is based in Sydney, Australia.
Donaco International Limited Fundamentals Summary
| DNA fundamental statistics | |
|---|---|
| Market cap | AU$43.83m |
| Earnings (TTM) | AU$5.69m |
| Revenue (TTM) | AU$33.87m |
7.6x
P/E Ratio1.3x
P/S RatioIs DNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DNA income statement (TTM) | |
|---|---|
| Revenue | AU$33.87m |
| Cost of Revenue | AU$12.50m |
| Gross Profit | AU$21.37m |
| Other Expenses | AU$15.68m |
| Earnings | AU$5.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0046 |
| Gross Margin | 63.10% |
| Net Profit Margin | 16.81% |
| Debt/Equity Ratio | 14.4% |
How did DNA perform over the long term?
See historical performance and comparison